IBS008738, a potent TAZ activator, stabilizes TAZ, elevates the unphosphorylated TAZ level, enhances the interaction of MyoD with the myogenin promoter, upregulates gene transcription regulated by MyoD, and competes with myostatin in C2C12 cells. Additionally, IBS008738 promotes myogenesis in C2C12 cells and facilitates muscle repair in a model of muscle injury.
BIBS-222, a nonpeptide angiotensin II (Ang II) receptor antagonist, appears to be an effective antihypertensive in the model of the renal hypertensive rat.
Lanraplenib succinate inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans. Lanraplenib succinate is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases.
Recilisib, also known as ON 01210.Na, is a radioprotectant, which modifys cell cycle distribution patterns in cancer cells subjected to radiation therapy, and it has been identified as a potential candidate for radiation protection studies. It appears tha
Ribociclib succinate hydrate is a highly specific CDK4 6 inhibitor (IC50s: 10 nM and 39 nM, respectively). It also is over 1,000-fold less potent against the cyclin B CDK1 complex.